Eton Pharmaceuticals, Inc.
ETON
$58.86
$18.0644.27%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 86.93M | 79.95M | 70.32M | 58.18M | 48.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 86.93M | 79.95M | 70.32M | 58.18M | 48.33M |
| Cost of Revenue | 35.02M | 32.12M | 30.53M | 21.27M | 18.92M |
| Gross Profit | 51.92M | 47.83M | 39.79M | 36.91M | 29.41M |
| SG&A Expenses | 36.51M | 35.24M | 33.27M | 30.45M | 26.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.01M | 75.12M | 68.91M | 56.22M | 49.04M |
| Operating Income | 6.92M | 4.83M | 1.41M | 1.96M | -710.00K |
| Income Before Tax | -1.49M | -4.56M | -6.48M | -4.03M | -4.50M |
| Income Tax Expenses | -11.00K | 43.00K | 199.00K | 101.00K | 89.00K |
| Earnings from Continuing Operations | -1.48 | -4.60 | -6.68 | -4.13 | -4.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.48M | -4.60M | -6.68M | -4.13M | -4.58M |
| EBIT | 6.92M | 4.83M | 1.41M | 1.96M | -710.00K |
| EBITDA | 11.09M | 8.88M | 4.79M | 4.61M | 1.22M |
| EPS Basic | -0.06 | -0.17 | -0.25 | -0.15 | -0.18 |
| Normalized Basic EPS | 0.08 | 0.03 | -0.06 | -0.03 | -0.07 |
| EPS Diluted | -0.07 | -0.18 | -0.26 | -0.17 | -0.19 |
| Normalized Diluted EPS | 0.06 | 0.01 | -0.06 | -0.03 | -0.07 |
| Average Basic Shares Outstanding | 108.01M | 107.61M | 106.81M | 105.82M | 104.70M |
| Average Diluted Shares Outstanding | 116.58M | 111.92M | 106.81M | 106.47M | 105.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |